What Are Infusion Centers and How Do They Work?

Infusion centers are outpatient medical facilities where patients receive medications delivered directly into the bloodstream through an intravenous (IV) line, though some centers also administer drugs under the skin or into muscle. They exist as standalone clinics, hospital-affiliated outpatient departments, and even within physician offices, and they treat a surprisingly wide range of conditions, from cancer to autoimmune diseases to rare genetic disorders. The experience of sitting in a recliner while medication drips through tubing for an hour or several hours is now routine for millions of people, yet most patients walk in the first time with little idea of what to expect.

Where Infusion Therapy Happens

Infusion therapy can be performed in several distinct settings: hospital outpatient departments, freestanding ambulatory infusion centers, physician offices, and patients’ homes.¹ Each setting has its own feel. A hospital outpatient department tends to be the largest and most resource-heavy, with immediate access to emergency services and specialists. A freestanding ambulatory center operates more like a clinic, often with a quieter, more streamlined atmosphere, and typically handles patients who are medically stable enough not to need a full hospital infrastructure around them. Physician offices sometimes have a few infusion chairs tucked into a dedicated room, especially in rheumatology or gastroenterology practices where infusion drugs are a core part of treatment.

Home infusion is the outlier. A nurse visits the patient’s house, sets up the IV equipment, and monitors the infusion on-site. For people in rural areas, home infusion can eliminate significant travel barriers that would otherwise make regular treatment difficult or impossible.² Not every drug qualifies for home infusion, though. Medications with a high risk of allergic reactions or those requiring complex monitoring usually stay in a clinical setting where nurses can respond quickly.

What a Typical Visit Looks Like

A first visit to an infusion center usually starts well before the medication begins flowing. You check in, provide insurance information, and are directed to a treatment area. A nurse reviews your medical history, current medications, and any recent lab work. In many centers, blood draws happen on-site that same day to confirm your body is ready for treatment. Vital signs are taken before, during, and after the infusion.

The nurse then places an IV line, usually in a vein on your hand or forearm, or accesses a pre-existing port or catheter if you have one. The medication bag is hung on a pole and connected to tubing that feeds into a programmable infusion pump. That pump controls the flow rate precisely, often starting slowly and increasing gradually, especially for drugs that carry a risk of infusion reactions. Depending on the drug and your condition, the infusion itself lasts anywhere from 30 minutes to several hours. Some chemotherapy regimens take an entire day.

Premedication is common. For drugs known to trigger allergic-type reactions, the nursing team may give you antihistamines, corticosteroids, or other agents beforehand. These premedication regimens have mostly been developed through clinical experience rather than formal randomized trials, but evidence supports that combinations of antihistamines, corticosteroids, and related drugs reduce both the frequency and severity of reactions.³ After the infusion finishes, you are typically monitored for an additional 15 to 60 minutes before being discharged.

Conditions Treated at Infusion Centers

Cancer treatment is probably the first thing people associate with infusion centers, and for good reason. Chemotherapy remains one of the most common infusion-delivered treatments, and oncology infusion suites are among the busiest clinical spaces in medicine. The logistics of chemotherapy infusions are complex enough that long wait times on the day of an appointment are a recognized challenge at cancer centers.⁴ But cancer is far from the only reason people use infusion centers.

Autoimmune and inflammatory conditions account for a large share of infusion center traffic. Drugs like infliximab and rituximab, used for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, multiple sclerosis, and lupus, are given by IV infusion on schedules that range from every few weeks to every several months. Patients with primary immunodeficiency disorders receive regular immunoglobulin infusions to replace the antibodies their bodies cannot make on their own. During the early months of the COVID-19 pandemic, a New York City infusion center tracked outcomes in over 2,000 patients receiving biologic infusions and found a low overall infection rate, with patients who had autoimmune conditions generally experiencing mild COVID cases.⁵ That finding helped reassure patients and physicians that continuing infusion therapy during the pandemic was generally safe.

Beyond these, infusion centers treat severe infections requiring IV antibiotics, iron-deficiency anemia with IV iron, osteoporosis with certain bone-building agents, and neurological conditions like myasthenia gravis. Some centers also administer IV hydration, enzyme replacement therapies for rare metabolic diseases, and, more recently, amyloid-targeting antibodies for Alzheimer’s disease.

Vascular Access Devices

If you need infusion therapy for a short course, a standard IV catheter placed in a forearm or hand vein each visit works fine. But for treatments that stretch over months or years, repeated needle sticks become painful and damage veins. That is where longer-term vascular access devices come in.

The two most common options for cancer patients and others on extended infusion schedules are peripherally inserted central catheters (PICCs) and implanted port catheters. A PICC is a long, thin tube threaded through a vein in the upper arm until its tip sits near the heart. A port is a small device surgically implanted under the skin of the chest, with a catheter that runs into a large vein. Each visit, the nurse accesses the port by inserting a special needle through the skin into the device.

Ports tend to be the preferred choice for chemotherapy. A meta-analysis comparing the two found that PICCs were associated with higher rates of overall complications, catheter-related blood clots, and allergic reactions compared to ports.⁶ A randomized trial confirmed that PICCs carry a higher risk of deep vein thrombosis and other problems, especially in patients with solid tumors.⁷ Ports require a minor surgical procedure for placement, which is a trade-off, but for someone facing months of chemotherapy the lower complication rate often makes it worthwhile. PICCs still have a role for shorter treatment courses, particularly IV antibiotics, where the risk-benefit calculation shifts.

Safety Protocols and What Can Go Wrong

Infusion centers are built around layers of safety checks, because the drugs being delivered are often potent, and they are going directly into the bloodstream. The nursing staff typically holds specialized training in infusion therapy, and facilities follow standards such as those set by the Infusion Nurses Society. For centers that handle chemotherapy and other hazardous drugs, USP General Chapter 800 provides enforceable safety standards covering everything from how drugs are stored and prepared to how staff protect themselves from exposure.⁸

Two risks deserve special attention. The first is infusion reactions, which range from mild flushing and chills to severe anaphylaxis. The premedication protocols discussed earlier are the primary defense, but nurses also monitor patients closely during the first infusions of a new drug, when reactions are most likely. Rate adjustments, where the pump speed is lowered or paused, are a standard response to early signs of a reaction.

The second risk is extravasation, which occurs when medication leaks out of the vein and into surrounding tissue. With certain drugs, especially some chemotherapy agents classified as vesicants, extravasation can cause serious tissue damage. Guidelines call for an immediate response: stop the infusion, attempt to aspirate the leaked drug from the catheter, administer a drug-specific antidote if one exists, apply thermal compresses, and notify a physician.⁹ For certain chemotherapy extravasations, professional guidelines also recommend early referral to a surgeon or other specialist.¹⁰ Preventing extravasation comes down to careful IV placement, continuous monitoring, and asking patients to speak up immediately if they feel burning, stinging, or swelling at the IV site.

Pediatric Infusion Centers

Children present unique challenges for infusion therapy. Smaller veins, higher anxiety, and the need for weight-based dosing all add complexity. Pediatric infusion centers or pediatric wings within larger centers are designed to address these differences. A children’s hospital that implemented a standardized operating procedure for pediatric infliximab infusions built the protocol around six core standards: screening for active infections and worsening disease before each infusion, laboratory monitoring, correct dosing and delivery rate, vital sign monitoring at defined intervals, a plan for managing infusion reactions, and criteria for giving premedications or adjusting the infusion speed to prevent reactions.¹¹ That kind of structured approach matters because children are less able to articulate symptoms like tingling or chest tightness, so nurses rely heavily on vital signs and observation to catch problems early.

The physical environment matters, too. Child-friendly decor, play areas, and the presence of child-life specialists help reduce fear and make the experience more tolerable. For kids who need infusions every few weeks for years, making the center feel safe rather than threatening is not a luxury but a clinical priority.

How Facility Design Affects the Experience

Spending hours in a medical chair while medication drips into your arm is inherently stressful, and the physical environment has more impact on that stress than many people realize. A concept called evidence-based healthcare design applies research on how spaces affect patients’ well-being to the actual layout and aesthetics of clinical settings.

A pilot study at a rheumatology infusion room tested this directly. Researchers surveyed patients before and after modifying the room with new colors, decorative elements, artificial plants, and a water feature. After the redesign, scores on 17 out of 25 environmental measures improved significantly, and patients rated the atmosphere as more comfortable and psychologically safe. The overall environmental score rose substantially.¹² These are small details, but for patients who return every few weeks for months or years, they accumulate into a meaningfully different experience.

Larger design choices matter just as much. A cancer infusion center that shifted from an open floor plan to a pod-based layout saw improved satisfaction with privacy among both patients and nurses. The pod design reduced ambient noise, gave patients better visual and auditory separation from one another, and provided nurses with more dedicated workspace, which in turn improved their ability to concentrate.¹³ Privacy is a real concern during infusions. Patients sometimes receive difficult news, experience nausea or emotional distress, or simply want quiet, and an environment that supports that makes clinical care more humane.

Insurance Hurdles and Treatment Delays

One of the less visible but most frustrating parts of infusion therapy is the insurance process. Many infusion drugs are specialty medications that cost thousands of dollars per dose, and insurers often require prior authorization before approving treatment. That administrative step can delay care in ways that have real health consequences.

A study of patients with rheumatic diseases found that when prior authorization was required, the median time from treatment request to the first infusion was 31 days, compared to 27 days when no authorization was needed. When a prior authorization was initially denied, the delay stretched to a median of 50 days. Patients whose authorizations were denied also ended up taking substantially more corticosteroids in the following three months, a sign that they were managing worsening symptoms while waiting for the infusion drug to be approved.¹⁴ A separate study of patients with inflammatory bowel disease found that receiving IV therapy, as opposed to self-injectable or oral alternatives, was itself a risk factor for treatment delays, and insurance denials roughly tripled the odds of a delay.¹⁵

Geography compounds these access issues. Research on older adults who might benefit from newer Alzheimer’s infusion therapies found that people with lower incomes and those living in rural areas were significantly less likely to meet the combined travel and caregiver requirements needed to attend regular infusion appointments. Subcutaneous delivery, which can be done at home, was projected to increase overall access by up to about a third in relative terms, with the largest proportional gains for low-income and rural populations.¹⁶

Cost Differences Between Settings

Where you receive your infusion can dramatically affect the price. Hospital outpatient departments charge facility fees that freestanding ambulatory centers and physician offices do not, and the cost difference can be substantial for the same drug and the same clinical outcome. A matched cohort analysis across multiple chronic conditions found that patient outcomes were similar across settings, but costs were lower in non-hospital sites of care.¹ For patients with high-deductible insurance plans, this means that choosing a freestanding infusion center over a hospital outpatient department for the same treatment could save hundreds or even thousands of dollars per infusion out of pocket.

If your physician writes a prescription for an infusion drug and gives you a choice of setting, it is worth asking about the cost at each available site. Not all drugs can be given at all sites, and some patients with complex conditions genuinely need the hospital infrastructure, but for many routine infusions the freestanding center is a reasonable and cheaper alternative.

Smart Pump Technology

The infusion pumps used in modern centers are not the simple gravity-drip setups of decades past. Current smart infusion pumps contain drug libraries with pre-programmed dosing limits that alert the nurse if a setting falls outside the expected range for a given medication. The next step in this technology is interoperability, where the pump wirelessly connects to the facility’s electronic health record to receive medication orders directly, reducing the chance of errors during manual programming.

A systematic review found that smart pump interoperability reduced specific types of medication administration errors by roughly 15 to 55 percent, and cumulative reductions across all error types ranged from about 21 to 90 percent depending on the facility and its baseline compliance.¹⁷ The wide range reflects real-world differences in how well different hospitals had already been programming their pumps before adopting the new technology. But the direction is consistent: automating the link between the prescription and the pump reduces the human-error step that has historically been a weak point in IV medication delivery.

The Shift Toward Subcutaneous Alternatives

A quiet but significant trend in infusion therapy is the development of subcutaneous formulations of drugs that were originally IV-only. Subcutaneous injections go under the skin rather than into a vein, and patients can often learn to give them at home. This matters because it changes the entire infrastructure required for treatment.

An Australian analysis looked at what would happen if all inflammatory bowel disease patients receiving IV infliximab and vedolizumab transitioned to subcutaneous versions. The financial impact on the hospital was significant, a projected loss of over 2.7 million Australian dollars in revenue, but the capacity freed up was equally striking: over 5,200 hours of infusion chair time per year.¹⁸ That freed capacity could be redirected toward patients who genuinely need IV-only therapies, such as those receiving chemotherapy or immunoglobulin replacement.

This shift creates a tension that the healthcare system is still working through. Hospitals have financial incentives to keep patients coming in for infusions because those visits generate revenue. Patients, meanwhile, often prefer the convenience and lower cost of home injection when the clinical evidence supports it. For conditions where both delivery routes have demonstrated equivalent effectiveness, the trend toward subcutaneous options is likely to accelerate, especially as the access challenges for rural and lower-income patients become harder to ignore.

What Happened During the Pandemic

COVID-19 forced infusion centers to rethink nearly every aspect of how they operated. Oncology infusion centers faced a particularly difficult situation: patients on chemotherapy are immunocompromised and vulnerable to infection, but stopping treatment could be life-threatening. Centers responded with a combination of strategies including adjustments to medication administration schedules, reducing how often patients came in for lab work or drug monitoring, and, where clinically appropriate, shifting some infusions to home delivery.¹⁹

Some of these adaptations outlasted the emergency. Screening checklists, spaced scheduling, telemedicine pre-visit assessments, and expanded home infusion programs that were implemented as pandemic measures proved to have standalone value. They reduced crowding, improved efficiency, and gave patients more flexibility. Infusion centers in 2025 look and function differently from those of 2019, and much of the change traces back to lessons learned during that period.